Angiotensin-converting Enzyme 2 (ACE2) Expression in Tonsils and Adenoids

Tonsillectomy Clinical Trial

— ACE2-AVG  

Official title:

Study of the Expression of Angiotensin-converting Enzyme 2 (ACE2), a Cell Membrane Receptor for SARS-CoV-2 and the TMPRSS2 Serine Protease in Tonsils and Adenoids of Children and Adults

Clinical Trial Details — Status: Withdrawn

Administrative data

• NCT number: NCT04640610
• Other study ID #: APHP201032
• Status: Withdrawn
• Start date: June 30, 2021
• Est. completion date: June 30, 2021

Study information

• Verified date: June 2021
• Source: Assistance Publique - Hôpitaux de Paris
• Contact: n/a
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

The objective of the research is to study the expression of the ACE 2 receptor and the TMPRSS2 serine protease in the tonsils and adenoids of children and adults.

Description:

The entry point for SARS-CoV-2 into the body is the nasal and pharyngeal mucosa. Angiotensin-converting enzyme 2 (ACE 2) was quickly identified as the functional receptor for SARS-CoV-2. Furthermore, the TMPRSS2 serine protease is required for the anchoring of the S protein in cell lines. In addition, the most commonly used screening test is a test for viral RNA by RT-PCR on a nasopharyngeal sample because the viral load is high. The tonsils and adenoids could be a target organ of the virus. In order to study this hypothesis, the expression of ACE 2 and the serine protease TMPRSS2 will be sought in these tissues. In addition, children, generally at high risk of severe viral respiratory infections (RSV, influenza), have milder symptoms than older patients with SARS-CoV-2 infection. The reason for this difference remains elusive. But one of the hypotheses formulated is that the level of expression of ACE 2 and / or TMPRSS2 may differ between adults and children, the viral load seeming to be correlated with the severity of the attack. In order to study this hypothesis, we will therefore compare the level of expression of ACE 2 in the tonsil tissue of children and adults.

Recruitment information / eligibility

• Status: Withdrawn
• Enrollment: 0
• Est. completion date: June 30, 2021
• Est. primary completion date: June 30, 2021
• Accepts healthy volunteers: No
• Gender: All
• Age group: N/A and older

Eligibility

Inclusion Criteria:

• Children and adults, without SARS-CoV-2 infection, in whom an adenoidectomy and/or tonsillectomy is performed for their care in the hospitals of Assistance Publique-Hôpitaux de Paris participating in the study.
• Holders of parental authority of minor patients and adult patients not opposed to participation in the study.

Exclusion Criteria:

• N/A

Related Conditions & MeSH terms

• Adenoidectomy
• Tonsillectomy

Intervention

Other:
• Storage of operating waste
Storage of operating waste of adenoidectomy / tonsillectomy

Locations

Country	Name	City	State
France	Hôpital Mondor	Créteil
France	Hôpital Bicêtre	Le Kremlin-Bicêtre
France	HEGP	Paris
France	Hôpital Armand Trousseau	Paris
France	Hôpital Bichat	Paris
France	Hôpital Lariboisière	Paris
France	Hôpital Necker-Enfants Malades	Paris
France	Hôpital Pitié Salpêtrière	Paris
France	Hôpital Tenon	Paris

Sponsors (1)

Lead Sponsor	Collaborator
Assistance Publique - Hôpitaux de Paris

Country where clinical trial is conducted

France, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Expression of ACE 2 receptor and TMPRSS2 serine protease	Measurement of expression of ACE 2 receptor and TMPRSS2 serine protease in tonsils and adenoids labeled by immunofluorescence.	9 months
Secondary	Location of ACE 2 receptor and TMPRSS2 serine protease	Location of ACE 2 receptor and TMPRSS2 serine protease in tonsils and adenoids labeled by immunofluorescence.	9 months